Preference Among Users – Small Molecule Drug Substance
Source: ISR Reports
In Q32021, ISR asked API outsourcers which CDMOs they are currently working with, and if the choice were entirely up to them, which CDMO would they prefer to use for all small molecule drug substance manufacturing. The data show that Cambrex, Patheon, Lonza, STA Pharma and Pfizer CentreOne are each the preferred CDMO among roughly one-third of their current customers. To learn more about CDMO preference among users, follow the link to the Small Molecule API CDMO Benchmarking report preview.
VIEW THE INFOGRAPHIC!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Pharmaceutical Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more